Inogen Inc. (NASDAQ:INGN)’s share price traded down 0.9% during mid-day trading on Friday . The stock traded as low as $51.12 and last traded at $51.93, with a volume of 376,986 shares changing hands. The stock had previously closed at $52.40.

Several equities analysts have recently issued reports on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $52.00 price target (up previously from $46.00) on shares of Inogen in a research note on Tuesday, May 10th. Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th. Piper Jaffray Cos. assumed coverage on Inogen in a research note on Thursday, March 24th. They issued a “neutral” rating and a $46.00 target price on the stock. Leerink Swann reissued an “outperform” rating and issued a $60.00 target price on shares of Inogen in a research note on Wednesday, June 8th. Finally, Needham & Company LLC reissued a “strong-buy” rating and issued a $58.00 target price on shares of Inogen in a research note on Thursday, June 9th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $52.83.

The firm’s 50-day moving average is $48.29 and its 200 day moving average is $42.00. The company has a market capitalization of $1.03 billion and a PE ratio of 88.13.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Monday, May 9th. The medical technology company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.12 by $0.01. The firm earned $43 million during the quarter, compared to analysts’ expectations of $41.75 million. The firm’s revenue was up 27.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.08 earnings per share. Equities analysts anticipate that Inogen Inc. will post $0.60 earnings per share for the current fiscal year.

In other news, EVP Matt Scribner sold 4,102 shares of the company’s stock in a transaction that occurred on Friday, April 15th. The stock was sold at an average price of $48.62, for a total value of $199,439.24. Following the completion of the transaction, the executive vice president now directly owns 6,435 shares of the company’s stock, valued at $312,869.70. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Brenton Taylor sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 13th. The shares were sold at an average price of $48.00, for a total value of $312,000.00. Following the completion of the transaction, the executive vice president now directly owns 31,851 shares of the company’s stock, valued at $1,528,848. The disclosure for this sale can be found here.

Several institutional investors have added to or reduced their stakes in INGN. Wells Fargo & Company MN raised its position in Inogen by 93.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,002,254 shares of the medical technology company’s stock valued at $40,180,000 after buying an additional 483,304 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Inogen by 131.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 274,332 shares of the medical technology company’s stock valued at $10,998,000 after buying an additional 155,800 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its position in Inogen by 87.3% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 256,370 shares of the medical technology company’s stock valued at $10,278,000 after buying an additional 119,470 shares in the last quarter. Pembroke Management LTD acquired a new position in Inogen during the fourth quarter valued at about $10,118,000. Finally, Thornburg Investment Management Inc. raised its position in Inogen by 7.7% in the fourth quarter. Thornburg Investment Management Inc. now owns 230,995 shares of the medical technology company’s stock valued at $9,261,000 after buying an additional 16,500 shares in the last quarter.

Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems, such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.